EFFICACY AND TOLERABILITY OF BISOPROLOL IN COMPARISON TO METOPROLOL IN PATIENTS WITH STAGE-I HYPERTENSIO

Investigator (Rajiv KArnik)0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Be male or female between the ages 18 to 65 years;
•2)New patients (treatment naïve) with diagnosis of stage-I hypertension (SBP 140-159 mm Hg or DBP 90-99 mm Hg);
•3)Current physical examination and vital signs at screening that reveals no clinically significant abnormalities;
•4)Willing and able to follow the instructions and procedures of the study including 24 hour continuous ambulatory cardiac monitoring;
•5)Willing to give written informed consent prior to admission into the study; and
•6)If female of childbearing potential, must be using a reliable form of birth control and be willing to continue as such for the duration of the study.

•1. Confirmed diagnosis of unstable angina;
•2. History of Acute Myocardial Infarction (AMI) or cardiac surgery within the preceding 6 months;
•3. Has uncompensated congestive heart failure (CHF);
•4. Has uncontrolled atrial fibrillation;
•5. Having bradycardia defined as a pulse rate below 50 beats per minute;
•6. Has bronchial asthma or Chronic obstructive pulmonary disease (COPD);
•7. Has Insulin-dependent diabetes mellitus;
•8. Have a history suggestive of, or presence of significant, gastrointestinal, endocrine, neurological, liver, or kidney disease, or conditions known to interfere with the absorption, distribution, metabolism, or excretion of study drugs;
•9. Have a history of drug or alcohol dependency or psychological disease;
•10. Require regular use of medication (other than study medication) that interferes with the absorption and/or metabolism of study drugs (e.g., steroids);
•11. Participation in a clinical trial or use of an investigational drug within 30 days prior to admission to this study;
•12. Have any acute illness within 2 weeks prior to screening;
•13. Have known significant hepatic & renal impairment;
•14. Subjects who have participated in any clinical trial or use of an investigational drug within 30 days prior to admission to this study;
•15. Pregnant or lactating women.

发起方

Investigator (Rajiv KArnik)